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Abstract
This article investigates drug dosage individualization when the patient population
can be described with a random effects linear model of a continuous pharmacokinetic
or pharmacodynamic response. Specifically, we show through both decision-theoretic
arguments and simulations that a published clinical algorithm may produce better in-
dividualized dosages than some traditional methods of therapeutic drug monitoring.
Since empirical evidence suggests that the linear model may adequately describe drugs
and patient populations, and linear models are easier to handle than the nonlinear mod-
els traditionally used in population pharmacokinetics, our results highlight the potential
applicability of linear mixed models to dosage computations and personalized medicine.
ii
1. Introduction
In the pharmacological treatment of some chronic illnesses, the clinician must search for
an appropriate drug dosage D that, after being administered during a pre-specified time
period to a particular patient, will maximize the probability that a continuous phar-
macokinetic or pharmacodynamic response YD takes a value between two pre-specified
values l1 and l2. Examples of these treatments are those based on drugs having a nar-
row therapeutic range, which is the range of plasma (or blood) drug concentrations that
yield the desired pharmacological effect without toxicity; in this case, a pharmacokinetic
response of interest (YD) is usually the steady-state trough plasma drug concentration
in the patient, which is measured during routine therapeutic drug monitoring (TDM)
(Shirrell et al., 1999). For instance, when administering the antipsychotic drug cloza-
pine to a patient with schizophrenia, the clinician must make efforts to avoid plasma
clozapine concentrations in the patient reaching very low or high values, since low con-
centrations will not reduce psychotic symptoms and high concentrations will increase
the risk of severe sedation, seizures and other undesirable effects (Sabaawi et al., 2006).
In this example, D is clozapine dosage and YD is plasma clozapine concentration.
Another (classic) example in which the plasma (or blood) concentration of the
treatment drug is a response of interest may be found during the treatment for heroin
addiction based on methadone. An effective methadone-maintenance treatment requires
that the minimum methadone concentration in the patient’s blood be kept above the
threshold of heroin-withdrawal symptoms, and that the maximum concentration be
kept below the threshold of the appearance of narcotic effects (Dole, 1980). Whereas
low methadone concentrations do not overcome heroin-withdrawal symptoms and also
increase the risk of relapsing into heroin use, high concentrations will sedate the patient,
preventing him/her from enjoying a normal and fruitful life. In this example, D is
methadone dosage and YD is blood methadone concentration.
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There are pharmacological treatments in which the clinician wants to control
a continuous response other than plasma concentration of the treatment drug. An
example is the use of the anti-coagulant drug warfarin to prevent blood clotting in
patients with risk of thrombotic episodes. To monitor the treatment and adjust warfarin
dosage, regular blood tests must be performed to measure the clotting tendency of the
patient’s blood; this measure is usually given as an international normalized ratio, INR
(Cuadrado et al., 2000). The objective of dosage adjustment is to find an optimum
dosage that produces an anti-coagulation intensity between minimum and maximum
pre-specified values. Lower dosages than this minimum may not be effective (putting
the patient at risk of a new thrombotic episode), and higher dosages than the maximum
may produce serious hemorrhages. Here, D is warfarin dosage and YD is the INR, which
is a pharmacodynamic response of interest.
In the above examples and those similar, the clinician usually assumes that the
patient’s continuous response (drug plasma or blood concentration in the first 2 exam-
ples and INR in the third example) will become stable after administering a constant
drug dosage for a known, fixed period of time. Further, the clinician must take steps
to find a dosage that, after being administered for that period of time, maximizes the
probability that the patient’s response reaches a value that is not too low or too high,
and therefore maximizes the chance of relieving the illness symptoms and minimizes the
risk of experiencing undesirable or toxic effects. Finding this dosage is usually difficult,
since there is usually wide variability across individual patients in response to the same
pharmacological treatment. This response variability may be due to personal (e.g.,
age or gender), genetic, or environmental (e.g., drug-drug interactions) influences on
pharmacokinetic and/or pharmacodynamic parameters, or even to patient compliance
(Nies, 2001). Efforts have been made to develop drug-dosage individualization proce-
dures based on statistical models that take into account this variability (for a review,
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see Diaz et al., 2007). Among these procedures, those based on mixed effects models
seem to be very promising.
The application of mixed effects models to the individualization of drug dosages
was pioneered by Sheiner and his collaborators (see Vozeh et al., 1981; Sheiner and
Beal, 1982). Underlying this application is the basic idea that a random coefficient in a
mixed effects model can be viewed as a parameter that is a characteristic constant for
a particular patient in the population of patients, but that varies across patients (see
Sheiner and Beal, 1980; Whiting et al., 1986). According to this idea, the variability
of a random coefficient reflects a real variation in the biological and environmental
variables that shape each person in the population as an individual; variability is not
a mere mathematical artifact for dealing with a population’s heterogeneity. Thus, a
mixed effects model includes parameters with constant values representing the whole
population (fixed effects) and parameters with varying values whose particular values
represent particular patients (random effects). Usually, these parameters measure or
reflect patients’ pharmacokinetic or pharmacodynamic characteristics. For a history of
both the theory and applications of mixed effects models in pharmacology, see Pillai et
al., 2005.
In practice, any drug dosage individualization procedure based on a population
mixed effects model utilizes Bayes’ theorem. Before applying a procedure to a particu-
lar patient, the fixed effects and variance-covariance matrices of the random effects and
errors must be estimated by using one or more samples of patients, or using previous
pharmacological knowledge. Then, the estimated distribution of the random coeffi-
cients is conceived of as a prior distribution for these coefficients, and a few response
measurements (e.g., drug plasma concentrations) from the patient are used to compute
the conditional distribution of the random coefficients given those measurements. A
summary measure of this conditional distribution, such as its mean or mode vector, is
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considered a predictor of the true values of the patient’s coefficients, and therefore used
to compute the patient’s individualized dosage. According to this methodology, which
is usually called “Bayesian feedback”, a prior distribution models real-world random
variables (i.e., models the variability of some pharmacokinetic or pharmacodynamic pa-
rameters in the patient population). Thus, the prior distribution is not interpreted as
a representation of the clinician’s system of subjective beliefs about hypothetical, con-
stant population parameters, which would be an orthodox, classic interpretation of the
prior distribution underlying Bayes’ theorem. Failing to recognize that statistical prac-
tice may profit from these two different philosophical conceptions of prior distributions,
rather than from the latter one alone, may have contributed to a misunderstanding of
the Bayesian feedback methodology in the statistical community, which struggled for
decades to understand the philosophical implications of Bayes’ theorem.
Diaz et al. (2007) considered the individualization of a drug dosage when the
natural log of steady-state drug plasma concentration-to-dosage ratio can be described
using a random intercept linear model. In their model, it is assumed that no covariate
has a random effect. Specifically, the studied model was
log
(
YD
D
)
= α + βTX +  , (1)
where YD is a trough steady-state drug plasma concentration, D is the steady-state
dosage, X is a vector with r covariates, β is a vector with regression coefficients that
are population constants, and α is a characteristic constant of each patient. At the
population level, it is assumed that α is a N(μα, σ
2
α) random variable, and that  is an
intra-individual N(0, σ2 ) random error. Moreover, it is assumed that α is independent
of . Diaz et al. (2007) suggested interpreting the quantity γ = (α − μα)/σα as a
standardized, covariate-adjusted index of metabolic activity, and suggest a procedure
for empirically validating this index. (The faster a patient’s body eliminates the drug,
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the lower his/her value of γ.) This interpretation is a direct consequence of the idea
that random coefficients may be viewed as constants for a particular patient. In an
independent study, Hu and Zhou (2008) suggested a more precise interpretation of α
(and therefore of γ) and a rationale for using model (1) in dosage computations (see also
Hu et al., 2009). Assuming linear pharmacokinetics, if CL/F is the patient’s apparent
clearance, the quantity eα+β
TX is a multiple of (CL/F )−1. Thus, eα may be viewed
as the portion of CL/F that is not explained by the covariates in X. Therefore, γ is
a covariate-adjusted proxy for apparent clearance; and model (1) quantifies the effects
of covariates on apparent clearance (Hu and Zhou, 2008), which is the most important
pharmacokinetic quantity to consider when designing a dosage regimen for long-term
drug administration.
Diaz et al. (2007) proposed a clinical algorithm for drug-dosage individualization
based on model (1). The algorithm was deduced from decision-theoretic concepts and
consists of a series of steps that the clinician should follow in order to find an appro-
priate dosage for a particular patient, assuming that model (1) adequately represents
the patient population. Before applying the algorithm to a particular patient, the pop-
ulation parameters β, μα, σ
2
α and σ
2
 have to be estimated using a sample of patients.
A simulation study using a clozapine model built with a US patient sample suggested
that the algorithm will perform reasonably well, even including the possibility that
parameter estimates are not very close to the true parameter values, and even if cloza-
pine dosages are rounded to the closest multiple of the smallest dosage available from
clozapine manufacturers, 25 mg/day (2007).
A difficult problem when individualizing a drug dosage using a population mixed
effects model is to decide how many drug plasma concentrations to obtain from the
patient, such that an optimum dosage for the patient is computed. Solutions to this
problem usually are ad hoc or lack clear justifications. However, Diaz et al. (2007)
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provided a theoretical framework that enables a solution to this problem for model
(1). They introduced the concept of ω-optimum dosage for a patient with metabolic
index γ, which, for ω close to 1, is essentially a dosage D that nearly maximizes the
conditional probability P (l1 < YD < l2 | γ), where (l1 , l2) is the range of desired
plasma concentrations. Thus, the optimum number of plasma concentrations that must
be obtained from the patient is the one that allows computing an ω-optimum dosage
for a pre-specified, high proportion of patients in the population.
When discussing Diaz et al.’s article (2007), it is important to differentiate between
model (1) and their proposed algorithm for drug dosage individualization. Whereas the
former is a description of the patient population, the latter is a series of steps for finding
an optimum dosage for a particular patient. The algorithm’s applicability relies on the
assumption that model (1) correctly describes the population. Diaz et al. (2007) found
that model (1) was useful in studying the relationship between plasma concentrations
of the antipsychotic clozapine and the covariates gender and smoking, controlling for
clozapine dosage. In addition, Diaz et al. (2008) and Botts et al. (2008) suggest that
a slightly more general version of model (1) may be useful for investigating drug-drug
interactions. In particular, the model allowed the finding that smoking modifies the
size of the effect of the anticonvulsant valproic acid on plasma clozapine concentrations
(Diaz et al., 2008), and that it also modifies the size of the effect of the anticonvulsant
lamotrigine on the plasma concentrations of the antipsychotic olanzapine (Botts et
al., 2008). Hu and Zhou (2008) described an even more general version of model (1)
that included transformed covariates and both peak and trough steady-state plasma
concentrations. They proposed using their linear model to investigate the sensitivity of
results from population pharmacokinetics analyses, and studied 3 drugs (2 biologicals
and 1 small molecule) using large, multinational patient samples. However, although
the objectives of Hu and Zhou’s study did not include searching for empirical evidence
6
in favor of the linear model, they found a remarkable agreement between the conclusions
obtained by using this model and those obtained by using traditional, pharmacokinetic
non-linear models. In particular, the average covariate-based dosing adjustment factors
provided by linear and non-linear models were essentially the same regardless of the
investigated drug or covariate. The 4 above studies (Diaz et al., 2007, 2008; Botts et
al., 2008; and Hu and Zhou, 2008), which used a total of 6 different samples of patients
representing people from several countries and 5 different drugs, reported evidence of
relatively good fits of the random-intercept linear models to the data, although some
caution was advised when there was a possibility of comedication-time interactions (Hu
and Zhou, 2008; Botts et al., 2008).
Whereas there is empirical evidence supporting model (1) and some of its gener-
alizations, at least for some drugs, Diaz et al.’s algorithm has been tested only through
simulations (Diaz et al., 2007). However, the simulation results, the above theoretical
developments and evidence in favor of model (1) or similar models, and other authors’
successful application of Bayesian feedback, suggest that the algorithm is a potential
tool for clinical practice and TDM that deserves a closer investigation. In particular,
collaborative effort is necessary for precisely estimating population parameters using
large samples of patients from particular populations and for particular drugs, and it is
essential to compare the performance of the algorithm with that of currently accepted
methods that are regularly used in TDM.
Model (1) does not include covariates with random effects, i.e., covariates whose
corresponding regression coefficients vary across patients. In model (1), the heterogene-
ity of the individuals is determined only by differences in the intercepts (the α’s). This
is a limitation, because the model does not allow for the possibility of covariates whose
effects on YD vary among patients who have the same values on the other covariates and
are under the same dosage. In fact, additional analyses of the clozapine data in Diaz
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et al. (2008), which are described in Section 4 below, indicated that the goodness of
the fit of the random-intercept linear model described in these authors’ article may be
improved by incorporating random effects for some covariates, including smoking. In
particular, this suggests that smoking has an effect size on plasma clozapine concentra-
tions that varies from patient to patient and, perhaps more importantly, that the extent
to which smoking modifies the effect of valproic acid on plasma clozapine concentrations
may vary from patient to patient. We do not know whether this differential smoking
effect is due to differences in smoking behavior, to differences in personal, genetic or
environmental characteristics of the patients, or to all of these factors (although this
difference may not be due to the number of cigarettes smoked daily; Diaz et al., 2008).
However, the possible existence of covariates with random effects affecting a continuous
pharmacokinetic response has motivated us to investigate whether the drug-dosage in-
dividualization algorithm in Diaz et al. (2007) is applicable to the situation where the
patient belongs to a population that can be described by a linear model incorporating
covariates with random effects.
This article investigates the clinical algorithm proposed by Diaz et al. (2007),
and the use of linear mixed models in drug dosage individualization. Specifically, this
article has three objectives: 1) to describe how Diaz et al.’s algorithm can be applied
to situations where some clinical and demographic covariates have random effects on a
continuous pharmacokinetic or pharmacodynamic response YD, and to situations that
include the linear models fitted in Hu and Zhou (2008), Diaz et al. (2008) and Botts
et al. (2008) (in these 3 studies, the D in model (1) was replaced by Dd, where d
was a parameter that was estimated); 2) to report decision-theoretic arguments that
show that the above algorithm may produce better dosages than another method which
has traditionally been used in TDM; and 3) to compare the algorithm with this other
method using simulated populations of patients taking clozapine. With this article, we
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also want to highlight the potentially wide applicability of linear mixed models to drug
dosage computations and personalized medicine.
Although at present most of the applications of mixed effects models to drug-
dosage individualization have been restricted to plasma drug concentrations as the
response variable, other types of response are possible. Thus, in this article, we will
be concerned with continuous pharmacokinetic or pharmacodynamic responses that
can be assumed to become stable after an administration of a constant drug dosage
for a known fixed period of time. Hereafter, in model (1) and all models investigated
in this article, YD will represent the value of a (positive) continuous pharmacokinetic
or pharmacodynamic response measured after administering a constant drug dosage D
during such time period. Of course, this time period depends on the particular drug and
response. For instance, when the response is plasma (or blood) drug concentration, this
time period usually corresponds to at least 5 drug half-lives, and the drug concentrations
measured after that period are usually termed “steady-state” (Winter, 2004). However,
a continuous response may not necessarily be a drug plasma concentration, but may
be an index of efficacy or toxicity of the drug, a measure of clinical benefit or harm,
a clinical endpoint, or even a continuous surrogate marker (Molenberghs et al., 2008).
The basic goal of a drug-dosage individualization process is to determine an optimum
dosage D for a particular patient, which allows him/her to reach a response YD that
lies within a range of desired responses (l1 , l2). (The interval (l1 , l2) will be called the
target response range.)
In Section 2, we describe how Diaz et al.’s algorithm can be used in situations
where some covariates have random effects and/or the log of dosage has a fixed regres-
sion coefficient. In Section 3, the algorithm is compared with a popular TDM method
through theoretical arguments. In Section 4, a model of plasma clozapine concentra-
tions that has covariates with random effects is described, and some computations that
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are necessary for performing Diaz et al.’s algorithm are illustrated. In Section 5, sim-
ulations are used to compare the algorithm with the TDM method, assuming accurate
parameter estimates. The effects of estimation errors on the algorithm’s performance
are investigated through simulations in Section 6. Section 7 discusses empirical evidence
supporting the investigated linear model, and describes additional advantages of using
linear over non-linear models in drug dosage computations. Conclusions are in Section 8.
2. Applicability of Diaz et al.’s algorithm in a more general setting
This study considers the model
log (YD) = ψ + η
TZ + βTX + d log (D) +  , (2)
where  is defined as in model (1), Z and X are vectors with k and r (possibly trans-
formed) clinical or demographic covariates, respectively, β is a vector of regression
coefficients that are population constants, and d is a population constant. Here, ψ and
η are characteristic constants of a particular patient; they vary from patient to patient.
At the population level, it is assumed that ψ is a N(μψ, σ
2
ψ) random variable, that η
is a k-dimensional Nk(μη,V η) random vector, that (ψ, η) has a joint normal distribu-
tion, and that (ψ, η) and  are independent from each other. Please note that whereas
X includes only covariates with fixed effects (the elements of β), Z includes covariates
that have fixed effects (the elements of μη) and random effects (the elements of η−μη).
Therefore, in order for β and μη to be identifiable, we assume that none of the covariates
in X are in Z, and vice versa. In the traditional terminology of mixed linear models,
the vectors (μψ, μ
T
η , β
T , d)T and (ψ − μψ, (η − μη)T )T are called fixed and random
effects, respectively (Verbeke and Molenberghs, 2000), with the understanding that μψ
and ψ−μψ do not measure the “effects” of any real-world covariate because ψ represents
only an intercept. If YD is drug plasma concentration and linear pharmacokinetics is
assumed, d may be fixed at 1 (Hu and Zhou, 2008; Hu et al., 2009). Alternatively, the
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maximum likelihood estimator of d may be used to test the null hypothesis of linear
pharmacokinetics, d = 1; and d should be estimated if there is evidence of nonlinear
pharmacokinetics. When d = 1 and η ≡ 0, model (2) is essentially model (1); in this
sense, model (2) is a generalization of model (1).
For a fixed value of Z, if we denote α = ψ + ηTZ then model (2) can be rewritten
as
log
(
YD
Dd
)
= α + βTX +  , (3)
with α ∼ N(μα (Z), σ2α (Z)), where μα (Z) = μψ +μTη Z and σ2α (Z) = Var(ψ + ηTZ).
Thus, for fixed Z, model (3) is analogous to model (1), although in model (3) the
parameters of α depend on Z and the dosage D has been “transformed” to Dd. Now
assume that model (2) describes adequately a population of patients, and that a clinician
wants to find an appropriate, individualized dosage D for a patient who belongs to this
population and has a constant but unknown α. The above analogy and the fact that Z
is known and fixed throughout the entire individualization process, suggest that Diaz
et al.’s algorithm can be implemented in the following way in the context of model (2).
Here, it is assumed that the values of μα (Z), σ
2
α (Z), β, σ
2
 and d are known (or
have been estimated with acceptable precision before applying the algorithm), which
implies that the distribution N(μα (Z), σ
2
α (Z)) is our prior distribution of α. When
model (2) holds, the steps of the algorithm are as follows:
Step 1: By using α̂
′
1 = μα (Z) and C
∗
0 =
√
l1 l2, compute the initial dosage
D1 =
(
C∗0 e
− α̂ ′1−βTX
)1/d
. (4)
Next, administer D1 to the patient during an appropriate time period so that the
response becomes stable, and then measure the stabilized response YD1.
Step i, i ≥ 2: By using the dosage-response pairs (Dj , YDj), j = 1, 2, . . . , i − 1,
which were obtained in the i− 1 previous steps, compute the i-th dosage
11
Di =
(
C∗0 e
− α̂ ′i −βTX
)1/d
, (5)
where α̂
′
i is a predictor of α given by
α̂
′
i = (1− λi
√
ρ−1 − 1)
(
1
i− 1
i−1∑
j=1
log
(
YDj
Ddj
)
− βTX
)
+ λi
√
ρ−1 − 1 μα (Z), (6)
with
ρ = ρ(Z) = σ2α (Z)/{σ2α (Z) + σ2 } (7)
and λi , i ≥ 1, defined by Eq. (12) in Diaz et al. (2007). (We stress that, in the context
of model (2), ρ depends on Z.) Administer the new dosage Di to the patient until the
response stabilizes, and then measure the produced, stabilized response YDi. Since we
are assuming that model (2) holds, we have that YDi = D
d
i e
α+βTX+i, i ≥ 1, where
α = ψ + ηTZ is a constant number for the patient and the i’s are N(0, σ
2
 ). The i’s
are assumed to be mutually independent.
For i ≥ 2, α̂ ′i is the mean of the conditional distribution of α given log(YDj/Ddj )−
βTX , j = 1, . . . , i− 1. By using Eq. (3) and a decision-theoretic argument analogous
to the proof of Theorem 3.1 in Diaz et al. (2007), it can be shown that, when model
(2) holds, Diaz et al.’s algorithm is optimal in the sense that, at the i-th algorithm
step, α̂
′
i and C
∗
0 are the predictor α̂i of α and the target median patient’s response C0,
respectively, that minimize the Bayes risk function
R (α̂i , C0) = 1− P (l1 < YDi < l2), (α̂i , C0) ∈ Gi × (0, ∞) , (8)
where Gi is the set of all predictors α̂i of α that are normally distributed, satisfy E[α̂i] =
μα (Z) and are independent of i , and it is assumed that the interval (0, ∞) includes
any possible response. (Please keep in mind that the value of Z is fixed during the
whole dosage individualization process, since the algorithm is applied to a particular
patient.) Thus, essentially, Diaz et al.’s algorithm aims at finding a good predictor of α
in the sense that this predictor maximizes the clinician’s degree of confidence that the
response YD will fall within the target range (l1 , l2).
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Suppose that a population of patients satisfy model (2), and that a particular
patient from the population has characteristic constants ψ and η and, therefore, a
characteristic α = ψ + ηTZ. Assume that Diaz et al.’s algorithm is applied to this
patient. An important question is: How many algorithm steps are necessary to obtain
an appropriate dosage for the patient? This question is answered by using the concept
of ω-optimum dosage (Diaz et al., 2007). Specifically, in the context of model (2), for
0 < ω < 1, an ω-optimum dosage for the patient is a dosage D that satisfies
P (l1 < YD < l2 | γ) ≥ ω
{
sup i≥1 P (l1 < YDi < l2 | γ)
}
, (9)
where γ = [α − μα (Z)]/σα (Z) . Thus, when model (2) holds, the largest attainable
probability that the response of the patient reaches a value within the target range
(l1, l2) is m, and the minimum number of algorithm steps that are necessary to reach
an ω-optimum dosage for the patient is I(γ, ω), where m and I(γ, ω) are defined by
Eqs. (14) and (16) in Diaz et al. (2007), respectively. (Please observe that, besides
depending on γ and ω, I(γ, ω) depends on both m and ρ, where ρ is given by Eq. (7)
if model (2) holds.)
In practice, since the patient’s γ is unknown, it is necessary to stop the algorithm
at the earliest step that yields an ω-optimum dosage for at least a fraction p of patients,
0 < p < 1. When model (2) holds, the minimum number of algorithm steps that are
necessary to obtain an ω-optimum dosage for at least p× 100% of the patients in the
population is i∗, which is defined by Eq. (18) in Diaz et al. (2007). In practice, the
values of ω and p should be fixed close to 1 before starting the algorithm. [The above
statements can be proven analogously to the proof of Theorem 3.2 in Diaz et al., 2007.]
Please note that, in the context of model (2), i∗ depends on the particular value that
Z takes on in the patient, although i∗ does not depend on X. Moreover, although
the definition of an ω-optimum dosage given by (9) formally depends on an infinite
sequence of future dosages, only a finite number of administered dosages is needed to
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compute a dosage that has at least a p× 100% possibility of being ω-optimum for the
patient. This number is i∗ − 1.
3. A comparison with therapeutic drug monitoring
Diaz et al.’s algorithm may be considered an optimal method for dosage adjustment
in a TDM setting when the patient belongs to a population that satisfies model (2)
and YD is drug plasma concentration. To understand why this may be so, let us
compare Diaz et al.’s algorithm with a popular method for dosage adjustment which is
advocated in a number of pharmacology textbooks. This method, which assumes linear
pharmacokinetics, adjusts the patient’s dosage using the formula
Adjusted dosage =
Previous dosage
Measured concentration
C0 , (10)
where C0 is a target drug steady-state trough concentration. Let A and B be two
patients from a population that satisfies model (2) with d = 1, who are independently
treated with the drug. [The condition d = 1 insures linear pharmacokinetics (Hu and
Zhou, 2008; Hu et al., 2009).] Assume that the two patients have the same covariate
values in X and Z, and have the same but unknown value of α, where α = ψ + ηTZ, so
that the patients are closely comparable. Suppose that we want to obtain steady-state
trough plasma concentrations that fall within a target range (l1 , l2), and that patients
A and B are initially administered dosages D1 and Db,1 , respectively, where D1 = Db,1
and D1 is given by Eq. (4). Suppose that the dosage for patient A is adjusted n times
using Diaz et al.’s algorithm as described in Section 2 (using C∗0 as target concentration
and α̂
′
i as a predictor of α), and that the dosage for patient B is adjusted n times
using (10), where C0 may not be equal to C
∗
0 . The following argument shows that,
after any dosage adjustment, patient A will have a higher chance of reaching the target
concentration range than patient B.
Let (Di, YDi), i = 1, . . . , n + 1, be the dosage-concentration pairs obtained from
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patient A. Thus, YDi = Di e
α+βTX+i , i = 1, . . . , n + 1, where the i’s are mu-
tually independent random errors with a N(0, σ2 ) distribution. From patient B,
we obtain dosage-concentration pairs (Db,i , YDb,i), i = 1, . . . , n + 1, which satisfy
Db,i =
(
Db,i−1/YDb,i−1
)
C0 and YDb,i = Db,i e
α+βTX+b,i , where the b,i’s are N(0, σ
2
 )
random errors that may be reasonably assumed to be mutually independent and inde-
pendent of the i’s. But, for i ≥ 2,
YDb,i =
(
C0 e
− α̂i−βTX
)(
eα+β
TX+b,i
)
, (11)
where α̂i = log
(
YDb,i−1/Db,i−1
) − βTX . Thus, applying formula (10) is equivalent to
applying Diaz et al.’s algorithm, except that C0 and α̂i are used in place of C
∗
0 and α̂
′
i
[cf. Eq. (5) with d = 1]. Now observe that α̂i ∈ Gi , where Gi is defined after Eq. (8).
Thus, if C0 = C∗0 , then
P (l1 < YDb,i < l2) < P (l1 < YDi < l2) , (12)
for all i = 1, . . . , n + 1 (see proof of Theorem 3.1 in Diaz et al., 2007.) To see why
inequality (12) is also valid when C0 = C
∗
0 , denote α̂
′′
i =
1
i−1
∑i−1
j=1
(
log
(
YDj
Dj
)
− βTX
)
.
Note that E[ α̂i | α ] = α = E[ α̂ ′′i | α ]. For i ≥ 2, E[ (α̂i−α)2 | α ] = σ2 ≥ σ2/(i−1) =
E[( α̂
′′
i − α)2 | α ] . Thus, if C0 = C∗0 and i ≥ 2, E[(α̂i − α)2] ≥ E[(α̂ ′′i − α)2] >
E[(α̂
′
i − α)2] because α̂ ′i is a Bayes estimator of α under the squared error loss but
α̂
′′
i is not; since α̂i ∈ Gi , inequality (12) holds. Thus, there is a higher probability of
reaching the target concentration range when Diaz et al.’s algorithm is used instead of
formula (10).
Even more, a slight modification of the proof of Theorem 3.1 in Diaz et al. (2007)
allows proving that inequality (12) is also valid for i ≥ 2 when the initial dosage D1 is
other than that given by Eq. (4), provided that dosage adjustments for patient A are
performed using Eqs. (5) and (6) with i = 2, . . . , n + 1. This should not be a surprise,
because, in general, the distribution of YDj/Dj does not depend on the method used to
compute Dj , although, of course, the distribution of YDj does.
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A further modification of the proof also allows proving that if (Di, YDi), i =
1, . . . , n are n steady-state dosage-concentration pairs provided by patient A in other
circumstances, for instance, during a TDM that did not necessarily implement Diaz et
al.’s algorithm, and if YDi/Di, i = 1, . . . , n, are mutually and conditionally independent
given γ, then inequality (12) is also valid for i = n+1, provided that Dn+1 is computed
using Eqs. (5) and (6) with i = n+1. Interestingly, under these more general conditions,
if i∗ is given by Eq. (18) in Diaz et al. (2007) and n + 1 ≥ i∗, then the probability
that Dn+1 is ω-optimum is at least p, that is, Dn+1 still enjoys an optimality property;
however, due to inequality (12), Db,n+1 may not have this property. Finally, if n+1 < i
∗,
then the clinician may use Dn+1 as an initial dosage for patient A and perform at least
i∗ − n− 1 algorithm steps in order to obtain a dosage that is ω-optimum for patient A
with a probability of at least p.
In summary, our computations show that formula (5) may produce better results
than formula (10), even if the dosages and concentrations inputted to formula (6) are
not obtained through a complete or strict application of Diaz et al.’s algorithm. More-
over, if the number of dosage-concentration pairs is sufficient (≥ i∗), only 1 application
of formula (5) may be enough to obtain a desired dosage optimality, regardless of how
the pairs were obtained. The objective of a complete application of the algorithm,
however, is to ensure that the probability of the drug concentration falling within the
target range is maximized each time a dosage is computed.
4. Application to clozapine individualization
Clozapine is an antipsychotic drug used to treat patients with severe schizophrenia.
Diaz et al. (2008) fit a linear model with only a random intercept and fixed-effect
covariates to 415 steady-state (trough) plasma clozapine concentrations provided by
255 schizophrenia patients. Some schizophrenia patients need to be treated not only
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for their psychotic symptoms but also for depression with antidepressants or seizures
with anticonvulsants. Thus, the objective of the above study was to measure the size
of co-medication effects on plasma clozapine concentrations, using a measure of average
effect size that is also described in Botts et al. (2008) and de Leon et al. (2007a,
2007b) and is based on relative percentiles (Mun˜oz and Xu, 1996; Diaz et al., 2007).
The fitted model was similar to model (2), except that η − μη was assumed to be 0;
that is, no random effects for the investigated covariates were included. In Diaz et
al.’s study (2008), YD was the steady-state plasma clozapine concentration produced
by the clozapine dosage D, and the covariates included in the final model were: taking
fluoxetine, taking fluvoxamine, taking paroxetine, taking phenobarbital, taking valproic
acid, smoking, and the natural log of clozapine dosage (log(D)). All covariates except
the latter were dichotomous. Also, an interaction between taking valproic acid and
smoking was included in the model.
To examine whether some of the above covariates have random effects, we reana-
lyzed Diaz et al. (2008) data (Table 1). SAS PROC MIXED was used for computations
(Littell et al., 2006). As a result, we found that the model in Diaz et al. (2008) could be
improved by including random effects for the covariates, smoking and taking fluoxetine.
These random effects were statistically significant at the 0.05 level of significance. Also,
Akaike information criteria were 405.3 and 385.6 for the model in Diaz et al. (2008)
and the model with covariate random effects, respectively, suggesting that the latter fit
better. Table 1 describes the new model. Residual analyses suggested that the model
fit well. When the fifth column in Table 1 is compared with the corresponding col-
umn in Table 2 of Diaz et al. (2008), we observe that excluding the random effects of
smoking and taking fluoxetine from the model did not substantially affect the estimates
for the average effect sizes of all covariates included in the model. At the 0.05 level of
significance, the statistical significance of these estimates and of fixed-effect estimates
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was not affected either.
By using Eq. (14) in Diaz et al. (2007), l1 = 350 ng/ml, l2 = 600 ng/ml, and the
error variance σ2 of the model in Table 1, which includes random effects for smoking
(Z1) and taking fluoxetine (Z2), we obtain m = 0.90. Moreover, by using Eq. (7)
with Z = (Z1, Z2)
T , the values of ρ(Z) are calculated as ρ(1, 1) = 0.95, ρ(1, 0) = 0.93,
ρ(0, 1) = 0.91 and ρ(0, 0) = 0.88. Thus, if we use formulae (16) and (18) in Diaz et
al. (2007) as explained in Section 2, and assume that the model in Table 1 is used to
implement an individualization algorithm in particular patients, we can compute that
3 algorithm steps are sufficient to reach a 0.9-optimum dosage for at least 95% of the
patients, regardless of the value of Z. In other words, to calculate such a dosage for
a particular patient, only 2 blood samples would be required from the patient. [Note
that i∗ does not depend on Z in this particular example; however, in general, i∗ does
not always take on the same value for all values of Z.]
5. Computer simulations assuming accurate parameter estimates
We conducted a simulation study that compared the performance of Diaz et al.’s algo-
rithm with that of an iterative application of formula (10), assuming that the model
described in Table 1 is a reasonable representation of the patient population, and us-
ing l1 = 350 ng/ml and l2 = 600 ng/ml. The main purpose of these simulations was
to explore differences between the two approaches, using realistic values for model (2)
parameters. The issue of whether and how parameter estimates can be improved is out
of the scope of this article and is the topic of a great deal of research (see, e.g., Verbeke
and Molenberghs, 2000).
The simulation program was written with SAS/IML [SAS Institute, Inc., 2008].
For each combination of values of the covariates included in the model, a population
of 10000 patients that satisfied the model was simulated. Specifically, a simulated
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realization of the random vector (ψ, η) represented “a patient”. In the two approaches,
initial dosages were computed with formula (4) (Table 2). For each hypothetical patient,
the clozapine dosage was adjusted 3 times using Diaz et al.’s algorithm; that is, 4
steps of the algorithm were implemented. After each algorithm step i, the proportion
pi of patients whose steady-state plasma clozapine concentration reached the target
concentration range, 350-600 ng/ml was calculated, i = 1, . . . , 4. (That is, pi = P (350 <
YDi < 600)×100.) The “patients” were also used to simulate a traditional TDM in which
clozapine dosages were iteratively adjusted 3 times using formula (10) with C0 = C
∗
0 .
For this simulated TDM, the proportion of patients whose clozapine concentration
reached the target range after the (i − 1)-th dosage adjustment was computed and
denoted by qi, i = 2, 3, 4; and the proportion of patients who reached the target range
after receiving the initial dosage was denoted by q1. Since the initial dosages were
the same in both simulated clinical procedures, p1 = q1. Since oral clozapine dosages
are available as multiples of 25 mg, dosages computed with formulas (4) and (5), or
with formula (10), were rounded to their closest multiple of 25 before “administering”
them to the patients (that is, before using the model to compute the resultant plasma
clozapine concentrations). All dosages were of at least 25 mg/day.
Table 3 shows the simulation results for non-smokers. Specifically, the table shows
the obtained values of pi and qi, i = 1, . . . , 4, for each possible combination of covariate
values. As seen in Table 3, for any combination of covariate values, pi > qi, i = 2, . . . , 4.
For instance, after performing the third dosage adjustment with Diaz et al.’s algorithm
in non-smokers who were taking only valproic acid as a comedication, the proportion of
patients who reached the target concentration range was p4=84.4%. In contrast, after
the third dosage adjustment with formula (10) in comparable patients, the proportion
was lower, q4=68.6% (Table 3). In general, when compared with the dosage adjustments
performed with formula (10), the dosage adjustments performed with Diaz et al.’s
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algorithm always yielded dosages that had a substantially higher likelihood of producing
clozapine concentrations within the target range.
Interestingly, p1 < p2 < p3 < p4, regardless of the patient subpopulation (Table
3). In contrast, in most subpopulations, q3 ≈ q4. Thus, after 2 dosage adjustments, the
traditional TDM did not produce any additional improvement in the dosages. Diaz et
al.’s algorithm, however, was able to further improve the dosages in the third dosage
adjustment. Conclusions from the simulation results for smokers were essentially the
same as those from non-smokers.
In summary, even after accounting for the fact that oral clozapine dosages are
available only in discrete amounts that are multiples of 25 mg, Diaz et al.’s clinical
algorithm produced better dosages than a TDM based on formula (10), in that the
algorithm may produce substantially higher proportions of patients reaching the target
clozapine concentration range.
6. A comparison with traditional TDM under parameter estimation errors
In Section 5, the parameters used to compute dosages with Diaz et al.’s algorithm were
the same as those used to simulate the subjects’ pharmacokinetic responses to dosages
from both the algorithm and formula (10). Thus, it was assumed that the available
parameter estimates were very precise estimations of the true model parameters. In
practice, parameter estimates must be used by the clinician to compute dosages with
Diaz et al.’s algorithm; however, these estimates may not be exactly the same as the
true parameters that generate the actual pharmacokinetic responses via model (2).
Diaz et al. (2007) explored through simulations the effect of parameter estimation
errors on algorithm performance by using a model of plasma clozapine concentrations
that was built with data from a double-blind clozapine trial. Although they did not
compare the performance of their algorithm with that of other approaches, they found
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that, unless model parameters are very far from their estimates, the algorithm still
performs well when the estimates are used in dosage computations in place of the
true parameters. Specifically, even when the potentially true parameters were all at a
distance of 1 standard error from their estimates, there was a high probability that Di∗
be 0.9-optimum (Diaz et al., 2007). Considering that maximum likelihood estimators
are consistent and usually utilized in the estimation of linear model parameters, Diaz
et al.’s simulation results increase our confidence in their algorithm.
In this Section, we use simulations to compare Diaz et al.’s algorithm with formula
(10) under the assumption that the form of the linear model representing the patient
population is the same as that described in Table 1, but incorporating the possibility
that parameter-estimate values may not be exactly the same as the true parameter
values. Observe that the model in Table 1 has 13 real-valued parameters, including
variances and all elements of the fixed-effects vector. Following an approach to simula-
tion similar to that in Diaz et al. (2007; p. 2066), let ϑi , i = 1, . . . , 13, denote the true
parameters. Let ϑˆi be the estimate of ϑi and se(ϑˆi) its corresponding standard error,
i = 1, . . . , 13; these are numbers described in Table 1. For a fixed r > 0, consider the
set Sr of 13-tuples (ϑ1, . . . , ϑ13) for which the ratio (ϑˆi−ϑi)/se(ϑˆi) is either r or −r for
all i. That is, Sr is the set of all possible combinations of potentially true parameter
values that are at a distance of r standard errors from their corresponding estimates.
Observe that, for fixed r, Sr has 2
13 = 8192 elements.
As in Section 5, we used a target plasma clozapine concentration range of 350-
600 ng/ml; and p3 and q3 were defined as the proportion of patients who reached
this range after 2 dosage adjustments using Diaz et al.’s algorithm and formula (10),
respectively. (Recall that i∗ was estimated to be 3 in Section 4.) For each patient
subpopulation determined by the values of X and Z, and r = 0.2, 0.4, . . . , 1.6, 1.8,
we computed p3 and q3 for each element of Sr by assuming that such element was
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the true combination of parameter values. Each computation of p3 and q3 used 10000
simulated patients. A particular value of the vector (ψ, η), which represented a patient,
was generated by using the assumed true values of μψ, σ
2
ψ, μη and V η . Regardless of
the drug individualization method, the pharmacokinetic response of the patient to a
dosage D was simulated by first generating one value of the random error , using the
assumed true value of σ2 ; then, YD was computed with the formula D
d eα+β
TX+, using
α = ψ + ηTZ and the assumed true values of β and d. Independent random errors
were used across iterations of Diaz et al.’s algorithm or formula (10), and across the
two individualization procedures. Dosages were always rounded to the closest, positive
multiple of 25 before computing YD. To compute dosages with Diaz et al.’s algorithm,
parameter estimates in Table 1 were entered into formulas (4)-(7). (The parameter
estimates were not used to compute dosages with the traditional TDM approach, since
formula (10) does not require them.) As in Section 5, the initial dosages used in both
individualization procedures were those shown in Table 2, and we let C0 = C
∗
0 in formula
(10).
For fixed r, the number of elements of Sr for which p3 > q3 was computed,
divided by 213 and multiplied by 100; the resultant percentage, denoted by Ωr, was
interpreted as the proportion of potentially true parameter combinations in Sr under
which Diaz et al.’s algorithm outperformed formula (10) after 2 dosage adjustments.
Table 4 shows Ωr for all subpopulations and particular values of r. Remarkably, for
all patient subpopulations, Ωr > 98% when r ≤ 1.2. (Regardless of the subpopulation
investigated, Ωr = 100% when r ≤ 1.) Another computation showed that, when r ≤ 1,
the average of the differences p3 − q3, taken over all elements of Sr was ≥ 8.6%. This
suggests that, even if all true parameters are at a distance of 1 standard error from
their corresponding estimates in Table 1, a substantially higher percentage of patients
may reach the target concentration range if Diaz et al.’s algorithm is used in place of
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the traditional TDM method.
Starting from r = 1.0, Ωr gradually decreased as r increased. For instance, among
non-smokers who were taking phenobarbital as their only comedication, Ω1.0 = 100%
Ω1.2 = 99.9%, Ω1.4 = 88.6% , Ω1.6 = 78.0% and Ω1.8 = 75.0% (Table 4). However,
even when r = 1.6, which is an appreciable distance between an estimate and its corre-
sponding parameter, Ωr was relatively large in most subpopulations of patients (Table
4). In fact, for 56 out of the 64 subpopulations, Ω1.6 ≥ 80%; for all subpopulations,
Ω1.6 ≥ 75%.
We conclude that if the true values of the parameters of the clozapine model re-
ported in Table 1 are not very far from the reported estimates (i.e., ≤ 1.2 standard
errors), Diaz et al.’s algorithm will still be superior in performance to the traditional
individualization approach based on formula (10). If moderately higher levels of error
affected parameter estimation (between 1.2 and 1.6 standard errors), there is still an ac-
ceptable likelihood that the former outperforms the latter approach. These simulation
results are consistent with those of Diaz et al. (2007), who found that their algorithm
is robust to errors in the estimation of model parameters, at least in the context of
clozapine individualization.
7. Discussion
This article examines the algorithm proposed by Diaz et al. (2007), which is a ratio-
nal approach to computing individualized optimum dosages that is based on a precise
definition of dosage optimality. Diaz et al. (2007) assumed that the patient belongs
to a population that can be described by model (1). This model represents patients’
heterogeneity through both covariates and a random intercept. As described in Section
2, the algorithm can be applied to a more general situation, described by model (2),
which has 2 additional features: covariates with random effects that add more flexibility
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to heterogeneity modeling, and a regression coefficient d for the log of dosage that may
reflect nonlinear pharmacokinetics when different from 1 (Hu and Zhou, 2008; Hu et
al., 2009). This suggests that Diaz et al.’s algorithm may have wide applicability.
According to Diaz et al.’s algorithm, once the parameters in model (2) are es-
timated using population data from phases III or IV, parameter estimates are used
to compute a recommended initial dosage D1. Then, after a few dosage adjustments,
these parameter estimates are combined with measurements from a particular patient
in order to compute a dosage that is optimum for the patient with a high probability.
Parameter estimates are also used in these dosage adjustments.
There is empirical evidence that model (2) may be a useful tool for describing the
effects of covariates on drug steady-state concentrations (Diaz et al., 2007, 2008; Botts
et al., 2008; Hu and Zhou, 2008). Some less general versions of this model have been
used to compute average dosage correction factors that allow incorporating covariate
information in the design of dosage regimes. Our results show that the model may
also be used to incorporate individual information that is not explained by available
covariates, which is modeled through random regression coefficients. This approach
may benefit some patients whose pharmacokinetic or pharmacodynamic characteristics
are considerably different from those of an average patient with comparable covariate
values.
A version of model (2) that is essentially a random intercept linear model was
used by Hu and Zhou (2008) in the analyses of phase III data from 3 different drugs;
their data were obtained from very large patient samples. Similar linear models were
used by Diaz et al. (2008) and Botts et al. (2008) in analyses of phase IV data. Hu and
Zhou (2008) used their linear model only as a method for investigating the robustness
of results obtained through compartmental pharmacokinetic models. However, they
found a close similarity between covariate-based, average dosage adjustment factors
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computed with compartmental models and those computed with their linear model,
which supports the validity of the linear model as a description of their patient samples
and investigated drugs. Thus, although Hu and Zhou did not originally intend to
gather evidence in favor of model (2), their work nicely provides very strong empirical
and theoretical support for this model. Hu and Zhou appear to be aware of this fact,
since they explicitly suggest the possibility that this model may be used to perform
primary analyses for regulatory submissions, at least in some situations. (These authors,
unfortunately, do not explicitly describe these situations.) This suggestion is also made
by Hu et al. (2009).
A reasonable explanation for the above similarity between results from model (2)
and those from compartmental models may be that, in the case of YD being steady-
state drug plasma concentration, model (2) is essentially a model of apparent clearance
when the drug follows linear pharmacokinetics, that is, when d is 1 or close to 1 (Hu
and Zhou, 2008; Hu et al., 2009), and apparent clearance is the main determinant of
the association between drug dosage and steady-state plasma concentrations (Winter,
2004). In Hu et al. (2009), an agreement between the pharmacokinetic conclusions
from linear and nonlinear modeling was also observed in a drug that did not follow
linear pharmacokinetics; in our opinion, this confirms the potentially wide applicability
of linear mixed models to drug dosage computations. In general, linear models are
easier to build and fit to phase III or IV data than the nonlinear models that are at the
core of traditional pharmacokinetic methods. Thus, model (2) may be a useful tool to
compute dosages that are adjusted for covariate values or other individual information.
The sparse sampling designs that usually characterize phase III and IV studies, which
impede a clear determination of absorption parameters (Jiao et al., 2009), may also be
a reason for preferring model (2) when using data from these studies. Sparse sampling
is also a reason for focusing only on steady-state concentrations when using phase III
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or IV data (Hu and Zhou, 2008; Jiao et al., 2009). Its use in primary analyses for
regulatory submissions is a potential application of model (2), as suggested by Hu and
Zhou (2008) and Hu et al. (2009). More research is needed to explore this possibility
and to examine whether the inclusion of covariates with random effects may provide
more precise dosage computations.
8. Conclusion
The main conclusion of this investigation is that, if model (2) holds, Diaz et al.’s algo-
rithm may produce better personalized dosages than some traditional dosage-adjustment
methods used in TDM. This conclusion, along with empirical findings showing that lin-
ear mixed models may provide accurate representations of pharmacokinetic data and
the fact that linear models are much easier to handle than the nonlinear models that
are traditionally used in population pharmacokinetics, suggest a potential use of linear
mixed models in drug dosage computation. Moreover, the results in Section 3 show that
the algorithm may easily be modified to incorporate steady-state concentrations previ-
ously measured through another dosage adjustment procedure, provided that there is
no evidence that apparent clearance or covariate values in the patient have substantially
changed. [If the values in X have not changed, the stability of apparent clearance may
be monitored by examining the stability of the empirical Bayes estimates of α, which
coincide with the α̂
′
i ’s when the algorithm is applied (Verbeke and Molenberghs, 2000)].
Also, if for some particular reason the clinician decides to change the dosage computed
with formula (5) at a particular algorithm step (perhaps because of an observed un-
wanted reaction from the patient, or just because he/she has to administer a dosage
rounded to the closest available dosage), the clinician may still incorporate the obtained
concentration into formula (6), treating this concentration as if it were one obtained
through an application of the algorithm. Our results show that the dosage computed
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at the next algorithm step will have the same optimality property as the dosage that
would be obtained if the clinician had not changed the dosage. Future clinical studies
that compare Diaz et al.’s algorithm with dosage-adjustment methods routinely used
in TDM are needed in order to quantify the clinical importance of differences between
dosages. More research is needed to investigate how to deal with changes in covariate
values or apparent clearance during an application of the algorithm; and to explore
the implications for the algorithm’s performance of not considering, at the population-
modeling stage, variables with important effects on YD.
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Table 1: Fixed effects and effect sizes (E) for variables significantly associated with the
natural log of plasma clozapine concentration, according to a linear mixed effects model
that includes random effects for smoking and taking fluoxetine (N = 255)a.
Variable Fixed effectsb 95%CIc,d Pvaluee Ef 95%CIg
Taking fluoxetineh 0.33 (0.15, 0.51) 0.0013 +39% (16, 67)
Taking fluvoxamineh 1.25 (1.04, 1.47) < 0.001 +249% (183, 335)
Taking paroxetineh 0.26 (0.12, 0.39) < 0.001 +30% (13, 48)
Taking phenobarbitalh −0.34 (−0.53,−0.14) < 0.001 −29% (−41,−13)
Taking valproic acidh 0.14 (0.014, 0.27) 0.03
- Non-smokers +15% (1, 31)
- Smokers −22% (−44, 8)
Smokingi −0.24 (−0.42,−0.055) 0.011
- Not taking valproic acid −21% (−34,−5)
- Taking valproic acid −47% (−62,−25)
Valproic acid-smoking
interaction −0.39 (−0.74,−0.038) 0.03
Log(dose) 1.23 (1.09, 1.38) < 0.001
95% CI = 95% confidence interval. This table looks similar to Table 2 in Diaz et al.
(2008) but describes a different model.
a Following the notation in Section 2, the model for plasma clozapine concentrations was
log(C) = α−0.24Z1+0.33Z2+1.25X1+0.26X2−0.34X3+0.14X4−0.39X5+1.23 log(D)+,
where Z1 = smoking , Z2 = taking fluoxetine, X1 = taking fluvoxamine, X2 = taking
paroxetine, X3 = taking phenobarbital, X4 = taking valproic acid, X5 = Z1X4, C =
plasma clozapine concentration, and D = clozapine dosage. The intra-individual varia-
tion, σ2 was 0.027 [95% CI, (0.022, 0.035)]. The mean of ψ was −1.05 (−1.89,−0.21). If
η is the vector of random regression coefficients corresponding to Z = (Z1, Z2)T , then
the variance-covariance matrix of the random effects, Var[(ψ − μψ, (η − μη)T )T ] was
a diagonal matrix whose components were as follows: variance of ψ, 0.20 (0.16, 0.26);
variance of the coefficient of smoking, 0.19 (0.10, 0.51); and variance of the coefficient
of taking fluoxetine, 0.083 (0.037, 0.34).
b The numbers in this column are the components of μη , β or d.
c 95% CI for the fixed effect.
d The standard errors of the fixed-effects estimators were 0.43 (intercept), 0.084
(taking fluoxetine), 0.11 (fluvoxamine), 0.068 (paroxetine), 0.099 (phenobarbital),
0.065 (valproic acid), 0.092 (smoking), 0.1770 (valproic acid-smoking interaction),
and 0.075 (log of dose). The standard errors of the variance estimators were 0.024
for the variance of ψ, 0.044 for the variance of the coefficient of taking fluoxetine,
0.076 for the variance of the coefficient of smoking, and 0.0034 for the intra-
individual variation.
e Tests the null hypothesis that the fixed effect is equal to 0 vs. the hypothesis that
it is different from 0.
f The effect size E measures the (adjusted) percentage change in the mean or
median (or any other percentile) of plasma clozapine concentrations due to co-
administration of the corresponding drug.
g 95% CI for E.
h The dichotomous variable was defined as 1 if the patient was taking the co-
medication and 0 otherwise.
i The dichotomous variable was defined as 1 if the patient was a smoker and 0
otherwise.
Table 2: Initial clozapine dosages (in mg/day) used in simulations. These dosages are optimal for
an “average patient” from a population that satisfies the model in Table 1 and a target steady-state,
plasma clozapine concentration range of 350-600 ng/ml.
Phenobarbital (No) Phenobarbital (Yes)
Valproic Acid Valproic Acid
Smokers Fluvoxamine Fluoxetine Paroxetine No Yes No Yes
No
No 350 300 450 400
No
Yes 275 225 350 300
Yes
No 250 225 350 300
No
Yes 200 200 275 250
No
No 125 100 175 150
Yes
Yes 100 100 125 125
Yes
No 100 75 125 100
Yes 75 75 100 100
No
No 425 500 550 675
No
Yes 325 425 450 550
Yes
No 325 400 425 525
Yes
Yes 250 325 350 425
No
No 150 175 200 250
Yes
Yes 125 150 150 200
Yes
No 125 150 150 175
Yes 100 125 125 150
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Table 3: Proportions of non-smokers who reached a target clozapine concentration range of 350-600
ng/ml under Diaz et al.’s algorithm (pi), and under a TDM method based on formula (10) (qi).
These simulations assume that the patients satisfy the model in Table 1.
PHENOB (No) PHENOB (Yes)
FLUVOX FLUOX PAROX Step i
VALPRO (No) VALPRO (Yes) VALPRO (No) VALPRO (Yes)
pi qi pi qi pi qi pi qi
No
No
No
1 42.1 42.1 43.5 43.5 43.7 43.7 42.6 42.6
2 76.7 66.4 75.8 65.9 75.6 66.6 76.1 65.6
3 82.2 68.1 81.6 67.7 81.7 68.3 81.9 68.8
4 84.2 68.9 84.4 68.6 84.8 68.4 84.3 69.2
Yes
1 43.1 43.1 42.9 42.9 42.7 42.7 42.20 42.2
2 76.8 65.8 76.2 65.8 77.1 66.8 76.4 66.3
3 82.2 68.2 81.2 69.1 82.3 68.4 81.5 68.9
4 83.8 69.3 84.1 69.0 84.7 68.6 84.1 69.4
Yes
No
1 36.8 36.8 37.5 37.5 37.5 37.5 37.5 37.5
2 75.6 64.7 75.8 64.1 76.5 63.8 76.3 65.1
3 81.7 68.5 80.8 68.0 82.2 68.5 81.6 68.0
4 84.0 68.5 84.2 68.5 85.0 68.9 84.5 68.5
Yes
1 36.3 36.3 36.3 36.3 37.2 37.2 37.1 37.1
2 74.7 64.4 74.8 63.9 76.2 65.3 75.3 64.0
3 81.0 68.1 80.9 68.1 81.3 68.5 81.2 67.3
4 83.6 68.3 82.8 68.2 84.3 68.4 83.5 67.9
Yes
No
No
1 43.2 43.2 40.8 40.8 41.1 41.1 42.2 42.2
2 74.1 64.3 72.5 63.5 76.1 64.8 74.4 64.8
3 78.7 65.8 78.0 67.0 80.3 67.9 79.4 66.6
4 80.7 66.0 80.9 67.0 83.2 68.4 82.0 68.2
Yes
1 43.2 43.2 40.8 40.8 42.6 42.6 42.4 42.4
2 72.0 63.9 71.8 62.5 74.0 65.2 73.7 64.8
3 77.4 65.3 75.6 64.1 80.2 66.9 78.9 66.8
4 78.5 66.2 77.3 64.4 81.3 66.3 80.9 66.9
Yes
No
1 36.8 36.8 35.2 35.2 37.3 37.3 36.4 36.4
2 71.0 61.4 70.0 60.2 73.5 63.0 73.0 62.7
3 75.6 64.4 73.9 63.7 78.9 67.0 77.0 65.7
4 77.8 64.5 75.7 63.8 80.5 67.8 79.4 65.4
Yes
1 37.5 37.5 36.2 36.2 37.2 37.2 36.3 36.3
2 69.0 59.1 68.1 59.0 72.1 61.9 70.7 61.1
3 73.4 62.5 71.4 61.5 76.7 64.3 75.4 64.3
4 75.3 62.5 73.7 61.5 78.5 64.8 77.1 64.5
FLUVOX: fluvoxamine; FLUOX: fluoxetine; PAROX: paroxetine; PHENOB: phenobarbital;VALPRO: valproic acid.
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Table 4: Proportion Ωr of combinations of potentially true parameters that are at a distance of r
standard errors from their estimates under which Diaz et al.’s algorithm outperformed formula (10)
after 2 clozapine dosage adjustments, for particular values of r and subpopulations of patients.
PHENOB (No) PHENOB (Yes)
FLUVOX FLUOX PAROX r
VALPRO (No) VALPRO (Yes) VALPRO (No) VALPRO (Yes)
NSMO SMO NSMO SMO NSMO SMO NSMO SMO
No
No
No
≤1.2 100 100 100 100 ≥99.9 100 ≥99.2 100
1.4 88.3 100 91.3 97.4 88.6 98.8 87.8 96.5
1.6 75.0 92.8 77.0 88.3 78.0 88.0 78.1 88.5
1.8 75.0 80.4 75.0 81.5 75.0 78.5 75.0 81.6
Yes
≤1.2 100 100 100 100 ≥99.5 100 ≥98.7 100
1.4 92.3 99.8 90.2 97.9 88.4 98.8 89.5 96.8
1.6 78.2 90.3 78.3 90.3 78.3 90.8 79.8 88.6
1.8 75.0 79.2 75.0 83.5 75.0 81.4 76.1 82.1
Yes
No
≤1.2 100 100 100 100 100 100 100 100
1.4 98.1 100 97.4 99.0 96.8 99.7 96.3 98.2
1.6 83.3 95.5 87.1 91.7 86.9 92.5 84.7 91.2
1.8 76.0 84.1 77.8 84.3 78.0 82.8 77.6 83.5
Yes
≤1.2 100 100 100 100 100 100 100 100
1.4 97.3 100 98.5 98.9 97.0 99.6 96.5 98.5
1.6 86.8 93.7 90.0 92.6 85.2 94.0 87.1 91.4
1.8 77.9 83.0 80.0 85.3 78.0 84.5 79.5 84.4
Yes
No
No
≤1.2 100 100 100 100 100 100 ≥99.0 100
1.4 93.6 99.9 91.2 97.8 92.9 99.1 92.0 97.7
1.6 81.4 94.4 81.4 90.7 83.6 92.2 83.1 91.1
1.8 75.4 84.9 76.7 84.0 78.1 83.0 77.5 84.4
Yes
≤1.2 100 100 100 100 ≥98.8 100 ≥99.2 100
1.4 93.6 99.8 94.7 98.3 91.7 98.9 93.2 97.9
1.6 84.1 93.9 85.9 92.0 82.6 91.5 84.5 91.1
1.8 77.9 84.8 79.7 85.3 76.9 83.2 79.0 84.7
Yes
No
≤1.2 100 100 100 100 100 100 100 100
1.4 98.9 100 97.6 99.4 98.1 99.6 96.2 98.3
1.6 90.1 97.2 88.5 94.2 90.4 95.0 87.5 92.1
1.8 82.4 89.0 80.8 87.4 82.2 86.6 80.2 85.1
Yes
≤1.2 100 100 100 100 100 100 100 100
1.4 98.3 100 99.0 99.3 97.5 99.6 98.1 98.7
1.6 90.8 96.6 92.2 95.0 88.9 95.2 91.3 93.0
1.8 82.2 88.6 84.3 88.4 81.6 87.2 84.0 86.6
FLUVOX: fluvoxamine; FLUOX: fluoxetine; PAROX: paroxetine; PHENOB: phenobarbital;VALPRO: val-
proic acid; NSMO: non-smoker; SMO:smoker.
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